埃克替尼治疗50例晚期复发非小细胞肺癌疗效分析

Curative effect analysis of icotinib on treatment of 50 cases of late recurrent non-small-cell lung cancer

目的:评价埃克替尼治疗晚期复发非小细胞肺癌的近期疗效及安全性。方法:回顾性分析晚期复发非小细胞肺癌患者50例资料,所有患者均口服埃克替尼125 mg,3次/d,直到病变进展或不能耐受。结果:本组50例患者均可评价疗效,客观缓解率(ORR:CR+PR)为40%,疾病控制率(DCR:CR+PR+SD)为78%。不良反应主要为皮疹和腹泻,多为Ⅰ、Ⅱ度,未见间质性肺病及血液学毒性出现。结论:埃克替尼是治疗晚期复发非小细胞肺癌NSCLC的有效药物,耐受性良好。

Objective： To evaluate the curative effect and safety of icotinib＇s treatment of late recurrent non-small-cell lung cancer.Methods： Retrospective analysis was conducted on 50 cases of late recurrent non-small-cell lung cancer patients. All the patients had orally taken icotinib 125 mg 3 times a day,until the disease progressed or the patients could not bear. Results： All the 50 cases were open to the evaluation of curative effect. The objective response rate（ ORR： CR ＋ PR） was 40% and the disease control rate（ DCR： CR ＋ PR＋ SD） was 78%. The main adverse reactions were rash and diarrhea,mostly degree I or II. No interstitial lung disease or hematologic toxicity occurred. Conclusion： Icotinib is an effective drug for the treatment of late recurrent non-small-cell lung cancer,with an advantage of nice durability.